Review Article Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/Signaling.2.050

A Brief Update on STAT3 Signaling: Current Challenges and Future Directions in Cancer Treatment

  • 1Yakult Central Institute, Yakult Honsha Co., Ltd., Tokyo, Japan
  • 2Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
+ Affiliations - Affiliations

Corresponding Author

Keisuke Taniguchi, keisuke-taniguchi@yakult.co.jp

Received Date: July 15, 2021

Accepted Date: August 27, 2021


Signal transducer and activator of transcription (STAT) 3 plays a key role not only in regulating a variety of biological properties, including survival, proliferation, and metastasis of cancer cells, but also in modifying the tumor microenvironment to promote angiogenesis and immunosuppression, rendering STAT3 a valuable target in cancer. In this review, we discuss the rationale for targeting STAT3 by presenting a succinct overview of STAT3 signaling, outlining an update concerning approaches to directly or indirectly targeting the role of this transcription factor, and highlighting challenges facing therapeutic strategies for inhibiting STAT3 in malignancies. Finally, we also discuss several state-of-the-art approaches for targeting oncogenic STAT3 signaling.


Cancer, STAT3, Signaling, Immunotherapy, Combination, YHO-1701

Author Information X